Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: Risk factors, monitoring, and healthcare implications

American Health and Drug Benefits

Volumn 4, Issue 5, 2011, Pages 292-302

  Riordan, Henry J ^a   Antonini, Paola ^a   Murphy, Michael F ^b  

^a Medical and Scientific Affairs   (United States)

^b Worldwide Clinical Trials   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; GLUCOSE; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SALBUTAMOL; TRIACYLGLYCEROL; ZIPRASIDONE;

DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEALTH CARE; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; MEDICAL INFORMATION; METABOLIC SYNDROME X; PATIENT MONITORING; POINT OF CARE TESTING; PREVALENCE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 80054680034     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. World Health Organization. Preventing chronic diseases: a vital investment. 2005. www.who.int/chp/chronic_disease_report/full_report.pdf. Accessed August 15, 2011.
2. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997; 171:502-508.
3. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
4. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia-a randomized double-blind controlled, short-term prospective study. Schizophr Res. 2008;101:266-272.
5. De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26:144-158.
6. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation (IDF), 2006. www.idf.org/ webdata/docs/IDF_Meta_def_final.pdf. Accessed August 15, 2011.
7. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther. 2010;127:210-251.
8. Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuro-psychopharmacol. 2006;16(suppl 3):S149-S155.
9. Hasnain MR, Vieweg WV. Acute effects of newer antipsychotic drugs on glucose metabolism. Am J Med. 2008;121:e17; author reply e19.
10. Prussian KH, Barksdale-Brown D, Dieckmann J. Racial and ethnic differences in the presentation of metabolic syndrome. J Nurse Pract. 2007;3:229-239.
11. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89:91-100.
12. de Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res. 2007;92:95-102.
13. Mulder H, Cohen D, Scheffer H, et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psy chopharmacol. 2009;29:16-20.
14. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone-and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425-433.
15. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008;101:273-286.
16. L'Italien GJ. Pharmacoeconomic impact of antipsychotic induced metabolic events. Prev Med Manag Care. 2003;3(suppl 2):S38-S42.
17. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223. Erratum in N Engl J Med. 2010;363:1092-1093.
18. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13:27-35.
19. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther. 2010;125:169-179.
20. Misawa F, Shimizu K, Fujii Y, et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects: a cross-sectional study. BMC Psychiatry. 2011;11:118.
21. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
22. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res. 2004;71:195-212.
23. Prochaska JJ. Smoking and mental illness-breaking the link. N Engl J Med. 2011; 365:196-198.
24. Morrato EH, Libby AM, Orton HD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry. 2008;165:42-50.
25. Cohn TA, Remington G, Zipursky RB, et al. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry. 2006;51:382-386.
26. Waterreus AJ, Laugharne JD. Screening for the metabolic syndrome in patients re-ceiving antipsychotic treatment: a proposed algorithm. Med J Aust. 2009;190:185-189.
27. Barnett M, VonMuenster S, Wehring H, et al. Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics. Ann Clin Psychiatry. 2010;22:9-18.
28. Suppes T, McElroy SL, Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists. Psychopharmacol Bull. 2007;40:22-37.
29. Druss BG, Marcus SC, Campbell J, et al. Medical services for clients in community mental health centers: results from a national survey. Psychiatr Serv. 2008;59:917-920.
30. McLellan RK, Comi RJ, Mackenzie TA, et al. The usefulness and cost of a shorter duration of fasting in workplace screening for glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract. 2009;84:e6-e8.
31. Goodman A. Diabetes screening of high-risk people is cost-effective. Am Health Drug Benefits. 2010;3 suppl:S1-S12.
32. Stahl S. The metabolic syndrome: psychopharmacologists should weigh the evidence for weighing the patient. J Clin Psychiatry. 2002;63:1094-1095.
33. Newcomer JW, Nasrallah HA, Loebel AD. The atypical antipsychotic therapy and metabolic issues national survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol. 2004;24(5 suppl 1):S1-S6.
34. Mackin P, Bishop DR, Watkinson HM. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry. 2007;7:28.
35. Straker D, Correll CU, Kramer-Ginsberg E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry. 2005;162:1217-1221.
36. Lin CC, Bai YM, Chen JY, et al. Easy and low-cost identification of metabolic syndrome in patients treated with second-generation antipsychotics: artificial neural network and logistic regression models. J Clin Psychiatry. 2010;71:225-234.
37. Vera-Llonch M, Delea TE, Richardson E, et al. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health. 2004;7:569-584.
38. Glazer WM. Point-of-care tests in behavioral health. Behav Healthc. 2006;26:37-39.
39. Schneiderhan ME, Batscha CL, Rosen C. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents. Pharmacotherapy. 2009;29:975-987.